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Purpose/Objective: Conformal radiotherapy involves 
irradiation of large volume of normal tissue with low and 
medium doses, which biological relevance is not clear yet. 
Here we aimed to compare effects associated with local body 
irradiation during treatment of two differently located solid 
tumors: head and neck cancer (HNC) and prostate cancer. 
Serum proteome features were used as a surrogate for 
general reaction of whole patient's organism to radiation. 
Materials and Methods: Here we compared effects 
associated with local body irradiation during RT of two solid 
tumors: head &neck cancer (HNC) and prostate cancer (PC). 
About 120 HNC and 120 PC patients were enrolled into the 
study. All patients were subjected to radical IMRT with 
maximum GTV doses in the range 50-73.8 Gy and 74-76 Gy, 
respectively. Acute mucosal toxicity and 
gastrointestinal/genitourinary toxicity was assessed. Three 
consecutive blood samples were collected before, during and 
after RT. The endogenous serum peptidome was profiled 
using MALDI mass spectrometry. Furthermore, serum proteins 
were analyzed using label-free LC-MS/MS 'shotgun' approach 
in complete sets of samples representing 20 patients from 
each cancer group. 
Results: In case of HNC patients radiation-induced changes in 
serum peptidome accumulated constantly during the 
treatment and their highest level was detected soon after 
the end of RT (~60% of components changed their abundance 
at significance level p<0.0001 between pre- and post-
exposure samples). Moreover, changes in serum peptidome 
correlated significantly with intensity of acute mucosal 
reactions and volume of normal tissue irradiated with low-to-
medium doses. In contrast, in case of PC patients majority of 
radiation-induced changes were detected 2-3 weeks after 
start of RT and their extend was less significant (~30% of 
components changed their abundance at significance level 
p<0.05). Furthermore, correlations between changes in serum 
peptidome and escalation of radiation toxicity or volume of 
tissues irradiated at low/medium doses were not detected. 
About 200 serum proteins were identified and quantified: 
~10% and ~2% of identified proteins changed their abundance 
between pre- and post-exposure samples from HNC and PC 
patients, respectively. 
Conclusions: The effects of local irradiation were 
documented at the level of serum proteome, which is an 
apparent indicator of the patient's whole body response. 
Significant differences were noted between patients 
irradiated because of HNC and PC in spite of the fact that 
similar volumes of tissues were irradiated with similar doses 
in both groups. This observation presumably reflected 
differences in radiosensitivity and corresponding early 
radiation toxicity in normal tissues/organs adjacent to cancer 
target and exposed to low-to-medium doses during IMRT. 
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Purpose/Objective: Treatment of lung cancer with 
combinations of surgery, chemotherapy, and radiotherapy 
(RT) is a major challenge because of dose limiting toxicities 
of the surrounding normal tissue, preventing tumor control. A 
better understanding of normal tissue damage response and 
repair after treatment is needed to improve local control, 
QoL and outcome. The NOTCH pathway is a key regulator of 
normal lung development and it is important in lung cancer 
progression and response to RT. Notch inhibitors are 
currently being tested in clinical trials but little is known on 
how normal lung tissue is affected. 
Materials and Methods: In order to study the effect of novel 
radio-sensitizers in different combination treatments on 
normal lung tissue we used a multilayer 'air-liquid interface' 
culture system from primary bronchial epithelial patient 
derived cells (PBEC). These cultures are typically composed 
of proliferative basal cells and the differentiated ciliated and 
mucous producing cells. The expression of Notch receptors, 
ligands and target genes was determined using qPCR and 
Immunoblotting. 
Results: Here, we studied cell population changes in the 
multilayer bronchial epithelium under normal conditions and 
after treatment with Notch inhibitors and/or radiation. Upon 
treatment with NOTCH inhibitors ciliated cells increased at 
the expense of the mucous lineage whereas Notch activation 
increased mucous cell populations. These changes were 
consistent with cell-type specific marker expression and 
NOTCH specific target gene expression. The data presented 
will be on the consequences of different scheduled 
treatments including Notch inhibitors and (fractionated) 
irradiation. 
Conclusions: The multilayer 'air-liquid-interface' culture 
system provides an ideal model for studying cell fate changes 
upon therapy in normal broncho-epithelial cells. The Notch 
pathway plays a key role on the regulation of the cell fate 
decision in our model.  
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Purpose/Objective: Radiotherapy is a key modality within 
the multidisciplinary management of breast cancer. A late 
effect (LE) following radiotherapy for breast cancer may 
occur many months or years afterwards, present significant 
management issues and adversely impact quality of life. To 
identify the LE prevalence, management and potential needs 
in breast survivorship an audit was performed of the patients 
referred to the Adult Radiation Late Effects Clinic at a 
tertiary care centre. 
Materials and Methods: Following institutional research 
ethics board approval, a retrospective review of a 
prospective radiation late effects research database was 
undertaken. Data regarding patient demographics, staging, 
clinical variables (surgery, systemic and radiotherapy), type 
and onset of late effect, LE management interventions, 
adverse events, and LE outcomes were abstracted. 
Descriptive and summary statistics, including range and 
percentage, were used in analyzing the patient 
characteristics and outcomes using SPSS 22. 
Results: From 02/2003 to 12/2012, 117 women were referred 
for LE consultation. Mean age at the time of LE referral was 
59 y (33-78) with 60 L, 46 R and 1 L and R and 20 in-situ and 
97 invasive cancers. Mean BSA was 1.75 (1.37-2.22) with 12 
smokers and 30 ex-smokers. T stage was: 20 Tis, 55 T1, 42 
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T2; and N stage was: 25 Nx, 65 N0, 26 N1, 1 N3. Mastectomy 
was performed in 17 and wide local excision in 100. Axillary 
dissection was done in 67 and sentinel node dissection in 33 
with a median number of 13 (1-24) lymph nodes excised. 52 
received chemotherapy and 72 endocrine therapy. All 
received radiotherapy (1 neo- and 116 adjuvant) with 67 
breast/chest wall alone and 40 breast/chest wall and 
regional nodal irradiation. The median time to onset of LE 
from the completion of radiotherapy was 0.5 y (0.1 to 7.8). 
LEs included: 38 truncal and/or breast pain; 24 arm 
lymphedema; 16 breast inflammation; 16 breast 
lymphedema; 14 neck, truncal, breast fibrosis; 9 tissue 
ulcer/necrosis; 2 brachial plexopathy 2; and 11 other. 
Following LE consultation, 90 received pharmacologic (18 
anti-inflammatory, 60 anti-oxidant, 12 pentoxifylline or 4 
other) and/or non-pharmacologic management (33 self-
lymphatic massage). Transient mild toxicities were observed 
in 8 (9%) (4 GI, 2 MSK, 2 pre-syncope). No major toxicities 
from LE treatment occurred. Moderate to significant 
improvement was observed in 78 (87%) with12 patients 
demonstrating no improvement. 
Conclusions: Following completion of therapy, acute 
toxicities may persistent or late toxicities arise. For women 
with these toxicities, current interventions appear to have a 
meaningful impact upon LE's with minimal side effects. 
Recognition of the potential to manage persistent acute 
effects and LE's is important and needs to be better 
incorporated within breast cancer survivorship to best 
improve aftercare. 
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Purpose/Objective: Survivors of Hodgkin lymphoma (HL) and 
subgroups of non-Hodgkin lymphoma (NHL) are at increased 
risk of various late adverse effects of radiotherapy and 
chemotherapy, leading to substantial excess morbidity and 
mortality. The need for long-term follow-up is increasingly 
recognized. Long-term follow-up care programmes have been 
established for childhood cancer survivors, but not yet for 
(N)HL survivors. Therefore, the Dutch BETER consortium 
(Better care after Hodgkin lymphoma: Evaluation of long-
term Treatment Effects and screening Recommendations) has 
developed a nationwide infrastructure for survivorship care 
clinics for survivors of HL and subgroups of non-Hodgkin 
lymphoma (diffuse large B-cell lymphoma). The consortium 
aims to: 1) establish evidence-based follow-up guidelines for 
(N)HL survivors; 2) identify and trace survivors eligible for 
follow-up care; 3) educate survivors about possible late 
adverse effects of treatment; and 4) provide risk-based care 
and advice regarding prevention. 
Materials and Methods: Follow-up guidelines were developed 
according to international standards. The guideline 
development group consisted of clinicians, methodological 
experts and patient representatives. We developed guidelines 
for second malignancies, cardiovascular disease, thyroid 
disease and osteoporosis after premature menopause. 
Recommendations are given for fertility care and family 
planning, therapy for neck muscle weakness, and infection 
prophylaxis for functional asplenia. 
Results: We are currently identifying and tracing a cohort of 
approximately 8,500 HL survivors and 3,000 NHL survivors in 
22 hospitals throughout the Netherlands, including all 
radiotherapy centres. Eligible patients for follow-up care 
survived for ≥5 years and were treated at ages 15-70 years 
from 1970 onwards. Survivors are identified through the 
Netherlands Cancer Registry, the nationwide pathology 
registry and hospital-based registries. Tracing of current 
addresses of survivors is done through the nationwide 
Netherlands Personal Records Database. For all survivors, 
treatment data are collected from medical records to provide 
risk-based screening recommendations. The website 
www.beternahodgkin.nl was developed to inform and 
educate survivors about late effects. Currently, a survivorship 
care plan is being developed. A nationwide database, 
including screening and adverse events data, is being 
developed to evaluate the follow-up guidelines for diagnostic 
value and efficacy. 
Conclusions: We expect that the BETTER project will 
improve healthy life expectancy and quality of life for (N)HL 
survivors. Evaluation of follow-up care will lead to improved 
knowledge regarding the diagnostic value and efficacy of the 
